<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635921</url>
  </required_header>
  <id_info>
    <org_study_id>HSP-2003-002</org_study_id>
    <secondary_id>HSP-2003-002</secondary_id>
    <nct_id>NCT00635921</nct_id>
  </id_info>
  <brief_title>Ziprasidone in the Treatment of Borderline Personality Disorder</brief_title>
  <official_title>Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>REM-TAP Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The aim of this double-blind, placebo-controlled study was to evaluate the&#xD;
      efficacy and tolerability of ziprasidone in the treatment of adult patients with Borderline&#xD;
      Personality Disorder (BPD).&#xD;
&#xD;
      Method: Sixty BPD patients were included in a 12-week, single-center, double-blind,&#xD;
      placebo-controlled study. The subjects were randomly assigned to ziprasidone or placebo in a&#xD;
      1:1 ratio following a two-week baseline period. The Clinical Global Impression scale for use&#xD;
      in BPD patients (CGI-BPD) was the primary outcome measure, and other scales and self-reports&#xD;
      related to affect, behavior, psychosis, general psychopathology domains and clinical safety&#xD;
      were included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The American Psychiatric Association (APA) Guidelines for the Treatment of Borderline&#xD;
      personality disorder recommend that pharmacological treatment for BPD has an important&#xD;
      adjunctive role, especially for diminution of symptoms such as affective instability,&#xD;
      impulsivity, psychotic-like symptoms, and self-destructive behavior. Studies conducted with&#xD;
      low doses of conventional antipsychotics have showed significant improvements in specific&#xD;
      symptoms such as hostility, impulsiveness, mood, and psychotic symptoms.&#xD;
&#xD;
      The introduction of atypical antipsychotics, with a more favorable tolerance profile,&#xD;
      increases clinicians' options for treating BPD. Olanzapine has proven its efficacy in four&#xD;
      double-blind, placebo-controlled clinical trials in patients with BPD. Ziprasidone is an&#xD;
      atypical antipsychotic with a pharmacological action on serotonergic, dopaminergic and&#xD;
      adrenergic receptors. It has proven to be effective for schizophrenia, schizoaffective and&#xD;
      acute mania disorders and the incidence of side effects is low.&#xD;
&#xD;
      Although clinical findings and the pharmacological activity of ziprasidone suggest the drug&#xD;
      may have therapeutic benefits in BPD patients, no controlled studies have yet been conducted&#xD;
      in these patients. We carried out a randomized, double-blind, placebo-controlled study to&#xD;
      evaluate efficacy and tolerability of ziprasidone in the management of BPD patients with&#xD;
      moderate-high clinical severity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CGI scale for use in borderline personality disorder (CGI-BPD)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale Depression (HAM-D-17)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale for Anxiety (HAM-A)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCL-90-R</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barratt Impulsiveness Scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UKU Side Effect Rating Scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EKG and laboratory assessment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Buss-Durkee Inventory</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>I ziprasidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>II placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziprasidone</intervention_name>
    <description>Dose flexible from 40 to 200 mg/d during 12 weeks</description>
    <arm_group_label>I ziprasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>flexible doses from 40 to 200 mg/d during 12 weeks</description>
    <arm_group_label>II placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-IV diagnosis of Borderline Personality Disorder&#xD;
&#xD;
          -  Age between 18 and 45 years&#xD;
&#xD;
          -  Clinical Global Impression of Severity (CGI-S)scores &gt;4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No comorbidity with schizophrenia, drug-induced psychosis, organic brain syndrome,&#xD;
             alcohol or other substance dependence, bipolar disorder, mental retardation, or major&#xD;
             depressive episode in course&#xD;
&#xD;
          -  current use of medically accepted contraception in the case of female patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry, Sta. Creu and St. Pau Hospital</name>
      <address>
        <city>Barcelona.</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <last_update_submitted>March 11, 2008</last_update_submitted>
  <last_update_submitted_qc>March 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</name_title>
    <organization>Víctor Pérez Sola</organization>
  </responsible_party>
  <keyword>Borderline Personality Disorder</keyword>
  <keyword>ziprasidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 28, 2011</submitted>
    <returned>February 24, 2011</returned>
    <submitted>January 21, 2013</submitted>
    <returned>February 22, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

